{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:29:53Z","timestamp":1790627393369,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Since symptomatic, non-antibiotic therapy has become an alternative approach to treat acute cystitis (AC) in women, suitable patient-reported outcome measures (PROM) are urgently needed. The aim of this part II of a larger non-interventional, case\u2013control study was the additional assessment of the ACSS as a suitable PROM.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from 134 female patients with diagnosed acute uncomplicated cystitis were included in the current analysis with (1) a summary score of \u201cTypical\u201d domain of 6 and more; (2) at least one follow-up evaluation after the baseline visit; (3) no missing values in the ACSS questionnaire data. Six different predefined thresholds based on the scoring of the ACSS items were evaluated to define \u201cclinical cure\u201d, also considering the draft FDA and EMA guidelines.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the six different thresholds tested, a summary score of the five typical symptoms of 5 and lower with no symptom more than 1 (mild), without visible blood in urine, with or without including QoL issues was favoured, which partially also could be adapted to the draft FDA and EMA guidelines. The overall patient\u2019s clinical assessment (\u201cDynamic\u201d domain) alone was not sensitive enough for a suitable PROM.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Scoring of the severity of symptoms is needed not only for diagnosis, but also for PROM to define \u201cclinical cure\u201d of any intervention, which could be combined with QoL issues. Results of the study demonstrated that the ACSS questionnaire has the potential to be used as a suitable PROM and should further be tested in prospective clinical studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-019-02948-8","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T13:02:41Z","timestamp":1569243761000},"page":"1977-1988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Additional assessment of Acute Cystitis Symptom Score questionnaire for patient-reported outcome measure in female patients with acute uncomplicated cystitis: part II"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-4877","authenticated-orcid":false,"given":"J. F.","family":"Alidjanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-5403","authenticated-orcid":false,"given":"K. G.","family":"Naber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8072-1841","authenticated-orcid":false,"given":"A.","family":"Pilatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1948-5792","authenticated-orcid":false,"given":"A.","family":"Radzhabov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zamuddinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-5529","authenticated-orcid":false,"given":"A.","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-4011","authenticated-orcid":false,"given":"P.","family":"Tenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-0797","authenticated-orcid":false,"given":"F. M.","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"2948_CR1","unstructured":"Bonkat G, et al (2019) EAU guidelines on urological infections. In: EAU guidelines edition presented at the EAU Annual Congress Barcelona. European Association of Urology"},{"issue":"3","key":"2948_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000487645","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz J et al (2018) The 2017 update of the german clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part ii: therapy and prevention. Urol Int 100(3):271\u2013278","journal-title":"Urol Int"},{"key":"2948_CR3","doi-asserted-by":"publisher","first-page":"h6544","DOI":"10.1136\/bmj.h6544","volume":"351","author":"I Gagyor","year":"2015","unstructured":"Gagyor I et al (2015) Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 351:h6544","journal-title":"BMJ"},{"issue":"5","key":"2948_CR4","doi-asserted-by":"publisher","first-page":"e1002569","DOI":"10.1371\/journal.pmed.1002569","volume":"15","author":"I Vik","year":"2018","unstructured":"Vik I et al (2018) Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial. PLoS Med 15(5):e1002569","journal-title":"PLoS Med"},{"key":"2948_CR5","doi-asserted-by":"publisher","first-page":"j4784","DOI":"10.1136\/bmj.j4784","volume":"359","author":"A Kronenberg","year":"2017","unstructured":"Kronenberg A et al (2017) Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 359:j4784","journal-title":"BMJ"},{"issue":"3","key":"2948_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000493368","volume":"101","author":"M Wagenlehner Florian","year":"2018","unstructured":"Wagenlehner Florian M et al (2018) Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (Fosfomycin Trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int 101(3):327\u2013336","journal-title":"Urol Int"},{"key":"2948_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/cid\/cis534","volume":"55","author":"T Cai","year":"2012","unstructured":"Cai T et al (2012) The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? Clin Infect Dis 55:771\u2013777","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2948_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.juro.2010.03.024","volume":"184","author":"F Sund\u00e9n","year":"2010","unstructured":"Sund\u00e9n F et al (2010) Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol 184(1):179\u2013185","journal-title":"J Urol"},{"key":"2948_CR9","volume-title":"Patient-reported outcome measures: use in medical product development to support labeling claims","author":"Food and Drug Administration","year":"2009","unstructured":"Food and Drug Administration (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Rockville"},{"issue":"2","key":"2948_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1159\/000356177","volume":"92","author":"JF Alidjanov","year":"2014","unstructured":"Alidjanov JF et al (2014) New self-reporting questionnaire to assess urinary tract infections and differential diagnosis: acute cystitis symptom score. Urol Int 92(2):230\u2013236","journal-title":"Urol Int"},{"issue":"1","key":"2948_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/antibiotics7010006","volume":"7","author":"JF Alidjanov","year":"2018","unstructured":"Alidjanov JF et al (2018) Reevaluation of the acute cystitis symptom score, a self-reporting questionnaire. Part I. Development, diagnosis and differential diagnosis. Antibiotics 7(1):6","journal-title":"Antibiotics"},{"issue":"1","key":"2948_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000493509","volume":"102","author":"JF Alidjanov","year":"2019","unstructured":"Alidjanov JF et al (2019) Reliability of symptom-based diagnosis of uncomplicated cystitis. Urol Int 102(1):83\u201395","journal-title":"Urol Int"},{"issue":"4","key":"2948_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000448591","volume":"97","author":"JF Alidjanov","year":"2016","unstructured":"Alidjanov JF et al (2016) The acute cystitis symptom score for patient-reported outcome assessment. Urol Int 97(4):402\u2013409","journal-title":"Urol Int"},{"issue":"2","key":"2948_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/antibiotics7020043","volume":"7","author":"JF Alidjanov","year":"2018","unstructured":"Alidjanov JF et al (2018) Reevaluation of the acute cystitis symptom score, a self-reporting questionnaire. Part II. Patient-reported outcome assessment. Antibiotics 7(2):43","journal-title":"Antibiotics"},{"key":"2948_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02761-3","author":"JF Alidjanov","year":"2019","unstructured":"Alidjanov JF et al (2019) Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women. World J Urol. \n                  https:\/\/doi.org\/10.1007\/s00345-019-02761-3","journal-title":"World J Urol"},{"key":"2948_CR16","volume-title":"Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, revision 3","author":"European Medicines Agency","year":"2018","unstructured":"European Medicines Agency (2018) Draft guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, revision 3. European Medicines Agency, Amsterdam. \n                  https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},{"key":"2948_CR17","first-page":"3","volume-title":"Uncomplicated urinary tract infections: developing drugs for treatment. Guidance for industry","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration (2018) Draft guidance. Uncomplicated urinary tract infections: developing drugs for treatment. Guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Washington, D.C, p 3"},{"key":"2948_CR18","volume-title":"Authors work certificate EU-01-000764: \u201cAcute cystitis symptom score (ACSS)\u201d","author":"JF Alidjanov","year":"2015","unstructured":"Alidjanov JF et al (2015) Authors work certificate EU-01-000764: \u201cAcute cystitis symptom score (ACSS)\u201d. International Online Copyright Office, European Depository, Berlin"},{"key":"2948_CR19","volume-title":"Standards of diagnosis and treatment of the urological diseases","author":"Ministry of Health of the Republic of Uzbekistan and Republican Specialized Center of Urology","year":"2016","unstructured":"Ministry of Health of the Republic of Uzbekistan and Republican Specialized Center of Urology (2016) Standards of diagnosis and treatment of the urological diseases. Republican Specialized Center of Urology, Tashkent"},{"key":"2948_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/biomet\/52.3-4.591","volume":"52","author":"SS Shapiro","year":"1965","unstructured":"Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (Complete samples). Biometrika 52:591\u2013611","journal-title":"Biometrika"},{"issue":"260","key":"2948_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","volume":"47","author":"WH Kruskal","year":"1952","unstructured":"Kruskal WH, Wallis WA (1952) Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47(260):583\u2013621","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2948_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1214\/aoms\/1177730491","volume":"18","author":"HB Mann","year":"1947","unstructured":"Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18(1):50\u201360","journal-title":"Ann Math Stat"},{"key":"2948_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform 12:77","journal-title":"BMC Bioinform"},{"key":"2948_CR24","unstructured":"Stevenson M et al (2017) epiR: tools for the analysis of epidemiological data"},{"key":"2948_CR25","volume-title":"R: a language and environment for statistical computing","author":"The R Development Core Team","year":"2017","unstructured":"The R Development Core Team (2017) R: a language and environment for statistical computing. CRAN, Vienna"},{"key":"2948_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-Verlag, New York"},{"issue":"1","key":"2948_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12955-017-0629-5","volume":"15","author":"A Holm","year":"2017","unstructured":"Holm A et al (2017) Development and validation of a condition-specific diary to measure severity, bothersomeness and impact on daily activities for patients with acute urinary tract infection in primary care. Health Qual Life Outcomes 15(1):57","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"2948_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/clpt.2011.195","volume":"90","author":"NE Rothrock","year":"2011","unstructured":"Rothrock NE, Kaiser KA, Cella D (2011) Developing a valid patient-reported outcome measure. Clin Pharmacol Ther 90(5):737\u2013742","journal-title":"Clin Pharmacol Ther"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-019-02948-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-019-02948-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T23:11:08Z","timestamp":1600729868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-019-02948-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2948"],"URL":"https:\/\/doi.org\/10.1007\/s00345-019-02948-8","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]},"assertion":[{"value":"28 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Prof. Kurt G. Naber, Prof. Florian M. Wagenlehner, Dr. Adrian Pilatz, and Dr. Jakhongir Alidjanov are authors and copyright holders of the ACSS questionnaire. Jakhongir Alidjanov declares a personal conflict of interest with Elsevier publishing company due to his personal disagreement with the policy of the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}